FDA gives emergency use authorization for Regeneron COVID-19 treatment

The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.It’s approved to treat mild and moderate COVID-19 for high-risk adults and pediatric patients ages 12 and older, the FDA said.The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.”Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.Monoclonal antibodies — proteins made in labs — help the immune system fight off pathogens.President Donald Trump celebrated the dose of experimental monoclonal antibodies he was given to help address his case of COVID-19. He said he thinks it helped him vanquish his coronavirus infection in record time.CNN contributed.

The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.

It’s approved to treat mild and moderate COVID-19 for high-risk adults and pediatric patients ages 12 and older, the FDA said.

The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.

“Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.

Monoclonal antibodies — proteins made in labs — help the immune system fight off pathogens.

President Donald Trump celebrated the dose of experimental monoclonal antibodies he was given to help address his case of COVID-19. He said he thinks it helped him vanquish his coronavirus infection in record time.

CNN contributed.

LEAVE A REPLY

Please enter your comment!
Please enter your name here